HC Wainwright Reaffirms "Buy" Rating for AngioDynamics (NASDAQ:ANGO)

AngioDynamics (NASDAQ:ANGO - Get Free Report)'s stock had its "buy" rating reaffirmed by investment analysts at HC Wainwright in a report issued on Wednesday,Benzinga reports. They currently have a $16.00 price target on the medical instruments supplier's stock. HC Wainwright's price target would indicate a potential upside of 84.12% from the company's current price. HC Wainwright also issued estimates for AngioDynamics' Q1 2026 earnings at ($0.14) EPS, Q2 2026 earnings at ($0.10) EPS, Q3 2026 earnings at ($0.08) EPS, Q4 2026 earnings at $0.02 EPS and FY2026 earnings at ($0.30) EPS.

Separately, Canaccord Genuity Group set a $17.00 target price on shares of AngioDynamics and gave the stock a "buy" rating in a research note on Wednesday.

AngioDynamics Stock Performance

Shares of NASDAQ ANGO traded down $0.05 during trading on Wednesday, reaching $8.69. 719,749 shares of the company traded hands, compared to its average volume of 589,754. The firm has a 50 day simple moving average of $9.86 and a 200-day simple moving average of $10.06. AngioDynamics has a 52-week low of $5.83 and a 52-week high of $13.50.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last issued its quarterly earnings data on Tuesday, July 15th. The medical instruments supplier reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.09. AngioDynamics had a negative net margin of 11.62% and a negative return on equity of 3.20%. The firm had revenue of $80.16 million for the quarter, compared to analysts' expectations of $74.26 million. During the same quarter in the prior year, the business earned ($0.06) EPS. The business's quarterly revenue was up 13.0% on a year-over-year basis. As a group, analysts anticipate that AngioDynamics will post -0.37 EPS for the current year.

Institutional Investors Weigh In On AngioDynamics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ANGO. Bank of New York Mellon Corp raised its position in shares of AngioDynamics by 3.2% during the fourth quarter. Bank of New York Mellon Corp now owns 122,676 shares of the medical instruments supplier's stock valued at $1,124,000 after buying an additional 3,815 shares during the last quarter. Squarepoint Ops LLC bought a new stake in shares of AngioDynamics during the fourth quarter valued at approximately $387,000. Ameriprise Financial Inc. raised its position in shares of AngioDynamics by 24.0% during the fourth quarter. Ameriprise Financial Inc. now owns 277,565 shares of the medical instruments supplier's stock valued at $2,542,000 after buying an additional 53,675 shares during the last quarter. GAMMA Investing LLC raised its position in shares of AngioDynamics by 1,281.4% during the first quarter. GAMMA Investing LLC now owns 13,897 shares of the medical instruments supplier's stock valued at $130,000 after buying an additional 12,891 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its position in shares of AngioDynamics by 0.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 329,090 shares of the medical instruments supplier's stock valued at $3,014,000 after buying an additional 2,270 shares during the last quarter. Institutional investors own 89.43% of the company's stock.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.